← Back to OncoGuides Main Platform
✓ Clinically Audited: August 2026 • OncoGuides Medical Advisory Board
Invasive Breast Cancer: Molecular Subtypes, Staging, Regimens & Biomarkers
Comprehensive 2026 clinical guidelines for HR+/HER2-, HER2+, and Triple-Negative Breast Cancer (TNBC).
1. Overview & Pathophysiology
Invasive breast carcinoma encompasses a heterogeneous spectrum of epithelial malignancies originating in the mammary terminal duct lobular units. In 2026, therapeutic stratification is governed primarily by biologic subtype: Hormone Receptor-Positive/HER2-Negative (HR+/HER2-, ~70%), HER2-Positive (HER2+, ~15%), and Triple-Negative (TNBC, ~15%). Prognostic staging integrates anatomical tumor size (T), nodal involvement (N), distant metastasis (M), alongside histologic grade, estrogen receptor (ER) status, progesterone receptor (PR) status, and HER2 expression.
2. Molecular Subtypes & Biomarker Profiling
Molecular profiling dictates modern breast oncology:
- Estrogen (ER) & Progesterone (PR) Receptors: Tested via Immunohistochemistry (IHC). Nuclear expression in >= 1% of tumor cells defines positivity and predicts response to endocrine therapy (Tamoxifen, Aromatase Inhibitors).
- HER2/neu (ERBB2): Assessed via IHC and in situ hybridization (FISH). IHC 3+ or IHC 2+/FISH-amplified defines HER2-positive status eligible for Trastuzumab/Pertuzumab. IHC 1+ or IHC 2+/FISH-negative defines 'HER2-Low' status eligible for Trastuzumab Deruxtecan (T-DXd).
- BRCA1/2 Germline Mutations: Directs poly(ADP-ribose) polymerase (PARP) inhibitor therapy (Olaparib, Talazoparib) in high-risk early or metastatic disease.
- PIK3CA & ESR1: Liquid biopsy (ctDNA) or tissue NGS detects activating PIK3CA mutations (guiding Alpelisib/Capivasertib) and acquired ESR1 ligand-binding domain mutations (guiding Elacestrant).
3. Standard-of-Care Treatment Protocols (NCCN/ASCO 2026)
| Subtype / Stage |
First-Line Systemic Regimen |
Adjuvant / Maintenance Therapy |
| Early HR+/HER2- (Node+) |
Dose-dense AC-T (Doxorubicin/Cyclophosphamide followed by Paclitaxel) if high genomic risk (Oncotype DX > 25) |
Aromatase Inhibitor (Letrozole/Anastrozole) + Abemaciclib (2 years) + Ovarian Suppression (GnRHa) if premenopausal |
| Metastatic HR+/HER2- |
Aromatase Inhibitor or Fulvestrant + CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib) |
Second-line: Capivasertib+Fulvestrant (PIK3CA/AKT1/PTEN) or Elacestrant (ESR1 mut) or T-DXd (HER2-low) |
| Early HER2+ |
TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab) neoadjuvant |
Trastuzumab + Pertuzumab (pCR) or T-DM1 (Ado-trastuzumab emtansine, if residual disease) |
| Early TNBC (Stage II-III) |
KEYNOTE-522 Regimen: Pembrolizumab + Carboplatin/Paclitaxel followed by AC |
Adjuvant Pembrolizumab (9 cycles) +/- Capecitabine or Olaparib (if gBRCA mut) |
4. Supportive Oncology & Organ Comorbidities
Multidisciplinary Supportive Care Links:
Managing therapy-induced organ toxicities is essential for maintaining dose intensity and overall survival:
- Cardiotoxicity & LVEF Monitoring: CardioOncoGuides (Anthracycline & HER2-induced cardiomyopathy).
- Renal Function & Cisplatin AKI: NephroOncoGuides (GFR calculators, TLS & hydration protocols).
- Pulmonary Toxicity & Pneumonitis: PulmonaryOncoGuides (ICI pneumonitis steroid tapers & Bleomycin DLCO).
- Cutaneous Toxicities & EGFR Rash: OncoDermatologyGuides (SCORTEN calculators, doxycycline tapers & scalp cooling).
- Chemotherapy Neuropathy (CIPN): NeuroOncoGuides (Duloxetine titration & cryotherapy).
- Cancer-Related Lymphedema: LymphedemaOncoGuides (Complete Decongestive Therapy CDT).
- Fertility Preservation: OncoFertilityGuides (Oocyte/sperm cryopreservation & GnRH-a).
- Psychosocial Support: PsychoOncoGuides (Distress Thermometer & free psychotherapy grants).
5. Patient & Caregiver Frequently Asked Questions
What is the difference between HER2-positive and HER2-low breast cancer?
HER2-positive breast cancer has high levels of the HER2 protein (IHC 3+ or FISH amplified) and responds to standard anti-HER2 therapies like Trastuzumab. HER2-low refers to tumors with minimal HER2 expression (IHC 1+ or IHC 2+/FISH-) that are now treatable with antibody-drug conjugates like Trastuzumab Deruxtecan (T-DXd / Enhertu).
How does an Oncotype DX score influence chemotherapy decisions?
The Oncotype DX 21-gene assay analyzes tumor tissue to predict the risk of distant recurrence. A Recurrence Score of 0–25 in postmenopausal women with hormone-receptor-positive node-negative disease demonstrates no significant benefit from adding adjuvant chemotherapy to endocrine therapy.
6. Primary Evidence & Guideline Citations
- Gradishar WJ, Moran MS, Abraham J, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2026. J Natl Compr Canc Netw. PMID: 35081512.
- Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9-20. PMID: 35665782.
- Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810-821. PMID: 32101663.